Immutep Limited

Contributing Author

Recent Articles by Immutep Limited

Jul-24	Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 IMMP GlobeNewswire
Jul-14	Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor IMMP GlobeNewswire
Jul-13	Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004 IMMP +7.52% GlobeNewswire
Jun-04	Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026 IMMP GlobeNewswire
May-28	Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients IMMP GlobeNewswire
Apr-30	Immutep Quarterly Activities Report Q3 FY26 IMMP GlobeNewswire
Apr-30	Immutep Receives Nasdaq Notice of Bid Price Deficiency IMMP GlobeNewswire
Apr-22	Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting IMMP GlobeNewswire
Apr-15	Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma IMMP +72.81% GlobeNewswire
Mar-19	Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases IMMP GlobeNewswire
Mar-13	TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis IMMP -82.44% GlobeNewswire
Feb-06	Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC IMMP GlobeNewswire
Jan-29	Immutep Quarterly Activities Report Q2 FY26 IMMP GlobeNewswire
Dec-22	Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study IMMP GlobeNewswire
Dec-16	Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace IMMP GlobeNewswire
Dec-08	Immutep and Dr. Reddy's enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa IMMP +26.11% GlobeNewswire
Dec-02	Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium IMMP -7.07% GlobeNewswire
Nov-13	Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025 IMMP GlobeNewswire
Nov-03	Immutep Receives A$4.6 million R&D Tax Incentive from French Government IMMP GlobeNewswire
Oct-29	Immutep Quarterly Activities Report Q1 FY26 IMMP GlobeNewswire
Oct-20	Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025 IMMP GlobeNewswire
Oct-20	Two Posters at ESMO Congress 2025 Highlight Immutep's Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer IMMP GlobeNewswire
Oct-13	Immutep Announces Successful Completion of FDA Project Optimus Requirements IMMP GlobeNewswire
Oct-09	Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer IMMP GlobeNewswire
Sep-22	Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti IMMP +6.21% GlobeNewswire
Sep-08	Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 IMMP GlobeNewswire
Aug-05	Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1 IMMP GlobeNewswire
Jul-30	Immutep Quarterly Activities Report Q4 FY25 IMMP GlobeNewswire
Jul-29	Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer IMMP GlobeNewswire
Jul-28	Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025 IMMP GlobeNewswire
Jun-23	Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases IMMP -5.00% GlobeNewswire
May-27	Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma IMMP GlobeNewswire
May-15	Immutep's Efti with KEYTRUDA (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer IMMP +8.20% GlobeNewswire
May-05	Immutep's Efti in Combination with KEYTRUDA (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1 IMMP +45.61% GlobeNewswire

Immutep Limited

Recent Articles by Immutep Limited

Upgrade your Finviz experience